ReviewAnnals of the New York Academy of Sciences2019
Vagal mechanisms as neuromodulatory targets for the treatment of metabolic disease.
Review in Annals of the New York Academy of Sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed.
- Anatomy and function of efferent and afferent vagal innervation of the stomach.Autonomic neuroscience : basic & clinical · 2026Review
- Supplementation of γ-Aminobutyric Acid as a Functional Nutrient.Nutrients · 2026Review
- Article
- From Adipose Dysfunction to Multi-Organ Steatosis: Defining the Metabolic Steatotic Axis.Current issues in molecular biology · 2026Review
- Liver-nervous system axis in MASLD: mechanistic insights and emerging targeted therapies.eGastroenterology · 2026Review
- How the gut microbiome shapes learning and memory: A comprehensive review.IBRO neuroscience reports · 2025Review
- Alteration of gut microbial ecology by the direct activation of the brain: Inverse gut-microbiome-brain dynamics.iScience · 2025Article
- Molecular and functional diversity of the autonomic nervous system.Nature reviews. Neuroscience · 2025Review
- Microbiome-derived metabolites in substance use disorders: Mechanisms and implications.Annals of the New York Academy of Sciences · 2025Review
- Vagal sensory neuron-derived FGF3 controls insulin secretion.Developmental cell · 2025Article
- Metabolic dysfunction associated fatty liver disease and type 2 diabetes: pathophysiological links, epidemiological trends, and clinical implications.Frontiers in endocrinology · 2025Review
- Electroceuticals: Unlocking the promise of therapies.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2024Review
- Hepatic vagal afferents convey clock-dependent signals to regulate circadian food intake.Science (New York, N.Y.) · 2024Article
- Molecular cell types as functional units of the efferent vagus nerve.Seminars in cell & developmental biology · 2024Review
- Stomach clusterin as a gut-derived feeding regulator.BMB reports · 2024Article
- Sympathetic circuits regulating hepatic glucose metabolism: where we stand.Physiological reviews · 2024Review
- Review
- Hepatic Innervations and Nonalcoholic Fatty Liver Disease.Seminars in liver disease · 2023Review
- Glucose Sensing in the Hepatic Portal Vein and Its Role in Food Intake and Reward.Cellular and molecular gastroenterology and hepatology · 2023Review
- Neuroimmunomodulation of vagus nerve stimulation and the therapeutic implications.Frontiers in aging neuroscience · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
With few effective treatments available, the global rise of metabolic diseases, including obesity, type 2 diabetes mellitus, and cardiovascular disease, seems unstoppable. Likely caused by an obesogenic environment interacting with genetic susceptibility, the pathophysiology of obesity and metabolic diseases is highly complex and involves crosstalk between many organs and systems, including the brain. The vagus nerve is in a key position to bidirectionally link several peripheral metabolic organs with the brain and is increasingly targeted for neuromodulation therapy to treat metabolic disease. Here, we review the basics of vagal functional anatomy and its implications for vagal neuromodulation therapies. We find that most existing vagal neuromodulation techniques either ignore or misinterpret the rich functional specificity of both vagal efferents and afferents as demonstrated by a large body of literature. This lack of specificity of manipulating vagal fibers is likely the reason for the relatively poor beneficial long-term effects of such therapies. For these therapies to become more effective, rigorous validation of all physiological endpoints and optimization of stimulation parameters as well as electrode placements will be necessary. However, given the large number of function-specific fibers in any vagal branch, genetically guided neuromodulation techniques are more likely to succeed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.